Friday, August 21, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· March 26, 2026

Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand

View original at seekingalpha.com
“The year ended with $24.1 million in cash and $29.4 million in working capital.”
Verbatim excerpt from the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Planning to increase sales force to be ramped up no later than the first part of Q3

    60% confidence

  • Emrosi achieved $14.7 million in net sales during the 3 quarters it was commercially available in 2025

    60% confidence

  • 2025 was a milestone year with successful launch of Emrosi

    60% confidence

  • Total net product revenue growth was 11% with gross margin improvement of nearly 3.5 percentage points versus 2024

    60% confidence

  • One or two product launches likely in the second half of 2026 with expenses already included in budget

    60% confidence

  • Approximately 100 million commercial covered lives have access to Emrosi

    60% confidence

  • Prescription volume for Emrosi grew nearly 50% sequentially in Q4 versus Q3

    60% confidence

  • Company expects improved reimbursement rates, reduced reliance on co-pay bridging program, and increase in Emrosi sales and operating margin expansion in 2026

    60% confidence

  • March prescriptions rebounded and Q1 prescriptions expected to surpass Q4 numbers

    60% confidence

  • Journey is well positioned to execute business plan and grow sales and profitability with current resources

    60% confidence

  • Total revenues for 2025 were $61.9 million, representing a 10% increase compared to $56.1 million for 2024

    60% confidence

  • Over 3,500 unique dermatology prescribers had written at least one script for Emrosi by year end

    60% confidence

  • Gross to net expected to improve gradually quarter-over-quarter throughout 2026 as national formularies adopt Emrosi

    60% confidence

Cited in these Via News reports